PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 18520954-7 2008 ACE inhibitors possessing a sulfhydryl moiety appear to have additional benefits in increasing nitric-oxide release and improving vascular endothelial function. Sulfhydryl Compounds 28-38 angiotensin I converting enzyme Homo sapiens 0-3 19596577-0 2009 Synthesis and enzymatic evaluation of novel partially fluorinated thiol dual ACE/NEP inhibitors. Sulfhydryl Compounds 66-71 angiotensin I converting enzyme Homo sapiens 77-80 16631159-5 2006 Based on recent observations with several anti-inflammatory and thiol-containing drugs, the present study was designed to test the hypothesis that anti-hypertensive agents from the angiotensin converting enzyme (ACE) inhibitors group inhibit the oxidative modifications of Apo B-100 caused by MPO. Sulfhydryl Compounds 64-69 angiotensin I converting enzyme Homo sapiens 181-210 18078750-1 2008 Screening of a metalloprotease library led to the identification of a thiol-based dual ACE/NEP inhibitor as a potent ACE2 inhibitor. Sulfhydryl Compounds 70-75 angiotensin I converting enzyme Homo sapiens 87-90 17506717-2 2007 In the early 1990"s, it was demonstrated that experimental radiation nephropathy could be treated with a thiol-containing ACE inhibitor, captopril. Sulfhydryl Compounds 105-110 angiotensin I converting enzyme Homo sapiens 122-125 16631159-5 2006 Based on recent observations with several anti-inflammatory and thiol-containing drugs, the present study was designed to test the hypothesis that anti-hypertensive agents from the angiotensin converting enzyme (ACE) inhibitors group inhibit the oxidative modifications of Apo B-100 caused by MPO. Sulfhydryl Compounds 64-69 angiotensin I converting enzyme Homo sapiens 212-215 16631159-7 2006 Only captopril, a thiol-containing ACE inhibitor, was able to significantly decrease the oxidative modification of LDL in a dose dependent manner and this by scavenging HOCl. Sulfhydryl Compounds 18-23 angiotensin I converting enzyme Homo sapiens 35-38 15545308-10 2004 This finding is not surprising based on the documented food effect with the sulfhydryl-containing ACE inhibitor, captopril. Sulfhydryl Compounds 76-86 angiotensin I converting enzyme Homo sapiens 98-101 15009531-0 2004 In vivo properties of thiol inhibitors of the three vasopeptidases NEP, ACE and ECE are improved by introduction of a 7-azatryptophan in P2" position. Sulfhydryl Compounds 22-27 angiotensin I converting enzyme Homo sapiens 72-75 12570791-3 2003 However, in the early 1990"s, it was demonstrated that experimental radiation nephropathy could be treated with a thiol-containing ACE inhibitor, captopril. Sulfhydryl Compounds 114-119 angiotensin I converting enzyme Homo sapiens 131-134 11207678-7 2001 Mercaptoethanol and dithiotreitol, two thiol-reducing agents, also efficiently protected ACE activity. Sulfhydryl Compounds 39-44 angiotensin I converting enzyme Homo sapiens 89-92 12040965-1 2002 Zofenopril calcium (CAS 81938-43-4) is a new angiotensin converting enzyme (ACE) inhibitor, which in addition to the typical activity of the class, proved to possess a specific cardioprotective effect due also to the presence of the sulfhydryl group. Sulfhydryl Compounds 233-243 angiotensin I converting enzyme Homo sapiens 45-74 12040965-1 2002 Zofenopril calcium (CAS 81938-43-4) is a new angiotensin converting enzyme (ACE) inhibitor, which in addition to the typical activity of the class, proved to possess a specific cardioprotective effect due also to the presence of the sulfhydryl group. Sulfhydryl Compounds 233-243 angiotensin I converting enzyme Homo sapiens 76-79 11145066-1 2000 Zofenopril is a pro-drug designed to undergo metabolic hydrolysis yielding the active free sulfhydryl compound zofenoprilat, which is an angiotensin converting enzyme (ACE) inhibitor, endowed also with a marked cardioprotective activity. Sulfhydryl Compounds 91-101 angiotensin I converting enzyme Homo sapiens 137-166 11145066-1 2000 Zofenopril is a pro-drug designed to undergo metabolic hydrolysis yielding the active free sulfhydryl compound zofenoprilat, which is an angiotensin converting enzyme (ACE) inhibitor, endowed also with a marked cardioprotective activity. Sulfhydryl Compounds 91-101 angiotensin I converting enzyme Homo sapiens 168-171 10698448-1 2000 Four primary zinc-binding pharmacophores (thiols, carboxylates, phosphorus acids, and hydroxamates) have been utilized in generating inhibitors of zinc metalloproteases such as ACE, NEP, the MMPs, and ECE. Sulfhydryl Compounds 42-48 angiotensin I converting enzyme Homo sapiens 177-180 10698448-2 2000 Although compounds which inhibit the activity of both ACE and NEP (vasopeptidase inhibitors, VPIs) have been reported which incorporate a thiol, carboxylate, or phosphorus acid pharmacophore, the generation of hydroxamate based vasopeptidase inhibitors has remained elusive. Sulfhydryl Compounds 138-143 angiotensin I converting enzyme Homo sapiens 54-57 8527265-3 1995 The thiol containing ACE inhibitor, captopril has been reported to inhibit isolated NADPH oxidase. Sulfhydryl Compounds 4-9 angiotensin I converting enzyme Homo sapiens 21-24 9749156-9 1998 To examine whether oxidation of thiol groups in the ACE molecule could be involved in the action of GRH, the effects of thiol reducing agents: mercaptoethanol and dithiotreitol (DTT) were investigated. Sulfhydryl Compounds 32-37 angiotensin I converting enzyme Homo sapiens 52-55 10087468-1 1999 The therapeutic actions of captopril are facilitated by its sulfhydryl moiety which interacts with the metal (Zn2+) prosthetic groups of angiotensin-converting enzyme (ACE; EC 3.4.15.1). Sulfhydryl Compounds 60-70 angiotensin I converting enzyme Homo sapiens 137-166 10087468-1 1999 The therapeutic actions of captopril are facilitated by its sulfhydryl moiety which interacts with the metal (Zn2+) prosthetic groups of angiotensin-converting enzyme (ACE; EC 3.4.15.1). Sulfhydryl Compounds 60-70 angiotensin I converting enzyme Homo sapiens 168-171 8138187-1 1993 In the present study, using the technique of EPR spin trapping with DMPO a spin trap, we demonstrated formation of thiyl radicals from thiol-containing angiotensin converting enzyme (ACE) inhibitor captopril (CAP) and from its stereoisomer epicaptopril (EPICAP), a non-ACE inhibitor, in the process of .OH radical scavenging. Sulfhydryl Compounds 135-140 angiotensin I converting enzyme Homo sapiens 152-181 7704183-1 1995 Scavenging of superoxide radical by angiotensin converting enzyme (ACE) inhibitor captopril (CAP), a thiol compound, was studied by several investigators and the results were contradictory; while some reported a high superoxide scavenging activity of CAP others found that CAP removed superoxide inefficiently. Sulfhydryl Compounds 101-106 angiotensin I converting enzyme Homo sapiens 36-65 7704183-1 1995 Scavenging of superoxide radical by angiotensin converting enzyme (ACE) inhibitor captopril (CAP), a thiol compound, was studied by several investigators and the results were contradictory; while some reported a high superoxide scavenging activity of CAP others found that CAP removed superoxide inefficiently. Sulfhydryl Compounds 101-106 angiotensin I converting enzyme Homo sapiens 67-70 8138187-1 1993 In the present study, using the technique of EPR spin trapping with DMPO a spin trap, we demonstrated formation of thiyl radicals from thiol-containing angiotensin converting enzyme (ACE) inhibitor captopril (CAP) and from its stereoisomer epicaptopril (EPICAP), a non-ACE inhibitor, in the process of .OH radical scavenging. Sulfhydryl Compounds 135-140 angiotensin I converting enzyme Homo sapiens 183-186 8138187-1 1993 In the present study, using the technique of EPR spin trapping with DMPO a spin trap, we demonstrated formation of thiyl radicals from thiol-containing angiotensin converting enzyme (ACE) inhibitor captopril (CAP) and from its stereoisomer epicaptopril (EPICAP), a non-ACE inhibitor, in the process of .OH radical scavenging. Sulfhydryl Compounds 135-140 angiotensin I converting enzyme Homo sapiens 269-272 1529807-2 1992 Captopril, an angiotensin converting enzyme (ACE) inhibitor, has free radical scavenging ability, attributable to its thiol group. Sulfhydryl Compounds 118-123 angiotensin I converting enzyme Homo sapiens 14-43 8462229-6 1993 ACE inhibitors can be subdivided into 3 classes with regard to the active group: the majority of ACE inhibitors are carboxyl-containing drugs, a new class of ACE inhibitors possess a phosphoryl-group and captopril and related compounds are sulfhydryl-containing drugs. Sulfhydryl Compounds 240-250 angiotensin I converting enzyme Homo sapiens 0-3 8393194-1 1993 The free radical scavenging effects of an angiotensin-converting enzyme (ACE) inhibitor containing sulfhydryl (SH; captopril) were compared with those of ACE inhibitors not containing SH (enalapril, enalaprilat, delapril and its de-esterified products). Sulfhydryl Compounds 99-109 angiotensin I converting enzyme Homo sapiens 73-76 1529807-2 1992 Captopril, an angiotensin converting enzyme (ACE) inhibitor, has free radical scavenging ability, attributable to its thiol group. Sulfhydryl Compounds 118-123 angiotensin I converting enzyme Homo sapiens 45-48 2359068-1 1990 Captopril, which is a thiol containing angiotensin converting enzyme (ACE) inhibitor that has a close structural similarity to D-penicillamine, behaves as a disease modifying antirheumatic drug (DMARD) in rheumatoid arthritis (RA). Sulfhydryl Compounds 22-27 angiotensin I converting enzyme Homo sapiens 39-68 2049244-2 1991 The currently available evidence shows that thiol containing ACE inhibitors are free radical (FR) scavengers in vitro; in particular the OH. Sulfhydryl Compounds 44-49 angiotensin I converting enzyme Homo sapiens 61-64 2261144-9 1990 The prototype orally active ACE inhibitor, captopril, is a sulfhydryl compound with a good safety profile at the recommended dosages but reported toxicity at higher dosages. Sulfhydryl Compounds 59-69 angiotensin I converting enzyme Homo sapiens 28-31 2188439-4 1990 Captopril, the first orally active, commercially available ACE inhibitor, is a sulfhydryl-containing compound. Sulfhydryl Compounds 79-89 angiotensin I converting enzyme Homo sapiens 59-62 2359068-1 1990 Captopril, which is a thiol containing angiotensin converting enzyme (ACE) inhibitor that has a close structural similarity to D-penicillamine, behaves as a disease modifying antirheumatic drug (DMARD) in rheumatoid arthritis (RA). Sulfhydryl Compounds 22-27 angiotensin I converting enzyme Homo sapiens 70-73 2194812-4 1990 Special attention is paid to the presence of the sulphydryl moiety of certain ACE-inhibitors. Sulfhydryl Compounds 49-59 angiotensin I converting enzyme Homo sapiens 78-81 2536279-1 1989 Captopril, an angiotensin converting enzyme (ACE) inhibitor, was hypothesized to be a potential scavenger of free radicals because of the presence of a thiol group. Sulfhydryl Compounds 152-157 angiotensin I converting enzyme Homo sapiens 14-43 2536279-1 1989 Captopril, an angiotensin converting enzyme (ACE) inhibitor, was hypothesized to be a potential scavenger of free radicals because of the presence of a thiol group. Sulfhydryl Compounds 152-157 angiotensin I converting enzyme Homo sapiens 45-48 2548550-8 1989 Determination of the positions of the thiol group conferring best inhibition in the active site of ACE permitted the probable location of the active site zinc ion to be identified. Sulfhydryl Compounds 38-43 angiotensin I converting enzyme Homo sapiens 99-102 2690907-12 1989 In fact, sulphydryl (-SH) containing ACE inhibitors such as captopril appear to act as scavengers of oxygen-derived free radical species thought to be important in the pathogenesis of both postischaemic contractile dysfunction and ischaemia/reperfusion induced myocyte necrosis. Sulfhydryl Compounds 9-19 angiotensin I converting enzyme Homo sapiens 37-40 2836111-3 1988 Three chemical classes of angiotensin converting-enzyme inhibitors have been introduced into clinical use, the sulfhydryl-containing inhibitors such as captopril and its analogs and prodrugs, carboxyalkyldipeptides such as enalapril and its analogs, and phosphorus-containing inhibitors such as fosinopril and the phosphonate SQ 29,852. Sulfhydryl Compounds 111-121 angiotensin I converting enzyme Homo sapiens 26-55 2827750-7 1987 The presence of sulfur----cobalt charge-transfer bands in both the visible absorption and magnetic circular dichroic spectra of the cobalt ACE-Captopril complex confirm direct ligation of the thiol group of the inhibitor to the active-site metal. Sulfhydryl Compounds 192-197 angiotensin I converting enzyme Homo sapiens 139-142 32940035-6 2020 The Zn(II)-IMAC system selectively bound the thiol-containing Zn(II)-ACE1 inhibitors captopril and omapatrilat, and the Fe(III)-IMAC system selectively bound the Fe(II)/(III)-5-LO inhibitor licofelone, demonstrating a remarkable IMAC-metalloenzyme metal ion match. Sulfhydryl Compounds 45-50 angiotensin I converting enzyme Homo sapiens 69-73 23965518-0 2013 The sulphydryl containing ACE inhibitor Zofenoprilat protects coronary endothelium from Doxorubicin-induced apoptosis. Sulfhydryl Compounds 4-14 angiotensin I converting enzyme Homo sapiens 26-29 2532461-0 1989 Cilazapril: a new non-thiol-containing angiotensin-converting enzyme inhibitor. Sulfhydryl Compounds 22-27 angiotensin I converting enzyme Homo sapiens 39-68 2485059-4 1987 These and more recently developed ACE inhibitors can be classified according to their structural analogy to dipeptides or tripeptides and according to the nature of their zinc-binding ligands, such as sulfhydryl, ketone, carboxylate, or hydroxyphosphinyl, that contribute greatly to their binding to ACE. Sulfhydryl Compounds 201-211 angiotensin I converting enzyme Homo sapiens 34-37 21629912-7 2011 This study reveals that both the selenol or thiol moiety and proline residues are essential for ACE inhibition. Sulfhydryl Compounds 44-49 angiotensin I converting enzyme Homo sapiens 96-99